Aclaris Therapeutics will present Phase 2a trial results of ATI-2138 for atopic dermatitis at the AAD Annual Meeting.
Quiver AI Summary
Aclaris Therapeutics, Inc. announced that an ePoster detailing the results from its Phase 2a trial of ATI-2138, a selective oral covalent inhibitor targeting ITK and JAK3, will be presented at the 2026 American Academy of Dermatology Annual Meeting in Denver. The poster will provide previously unreported findings from the trial focusing on patients with moderate-to-severe atopic dermatitis. Aclaris is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for immuno-inflammatory diseases, aiming to meet the needs of patients lacking effective options. Additional information about the company can be found on their website and LinkedIn.
Potential Positives
- Aclaris is presenting previously undisclosed results from its Phase 2a trial of ATI-2138, highlighting the company's commitment to advancing research in immuno-inflammatory diseases.
- The ePoster presentation at a prestigious conference such as the 2026 AAD Annual Meeting elevates Aclaris' visibility in the dermatology and biopharmaceutical sectors.
- This event provides an opportunity for Aclaris to engage with key stakeholders, potentially attracting interest from investors and collaborators in the biopharmaceutical community.
Potential Negatives
- The press release lacks details on the efficacy and safety of ATI-2138 from the Phase 2a trial, which could lead to skepticism about the product's potential.
- There is no mention of a timeline for further development or commercialization of ATI-2138, leaving investors uncertain about the future prospects.
- The focus on an open-label trial may raise concerns regarding the robustness of the data, as open-label studies are typically less rigorous than controlled trials.
FAQ
What is ATI-2138 developed by Aclaris Therapeutics?
ATI-2138 is a potent and selective investigational oral covalent inhibitor of ITK and JAK3 aimed at treating immuno-inflammatory diseases.
Where will the ePoster for ATI-2138 be presented?
The ePoster will be available during the 2026 American Academy of Dermatology Annual Meeting in Denver, CO.
What are the findings in the Phase 2a trial of ATI-2138?
The ePoster will include previously unreported results from a Phase 2a trial in patients with moderate-to-severe atopic dermatitis.
Who authored the study on ATI-2138?
The study was authored by a team including Ajay Aggarwal, Aparna Kaul, and others from Aclaris and Mount Sinai.
How can I learn more about Aclaris Therapeutics?
For more information, please visit www.aclaristx.com or follow Aclaris on LinkedIn.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ACRS Hedge Fund Activity
We have seen 55 institutional investors add shares of $ACRS stock to their portfolio, and 53 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,349,160 shares (-45.2%) from their portfolio in Q3 2025, for an estimated $8,263,404
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 1,898,561 shares (+379712.2%) to their portfolio in Q4 2025, for an estimated $5,714,668
- MARSHALL WACE, LLP removed 1,232,629 shares (-71.7%) from their portfolio in Q4 2025, for an estimated $3,710,213
- BLACKROCK, INC. added 1,113,489 shares (+19.6%) to their portfolio in Q4 2025, for an estimated $3,351,601
- AMERIPRISE FINANCIAL INC removed 959,391 shares (-75.1%) from their portfolio in Q4 2025, for an estimated $2,887,766
- LOGOS GLOBAL MANAGEMENT LP removed 900,000 shares (-60.0%) from their portfolio in Q4 2025, for an estimated $2,709,000
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 880,609 shares (+2430.1%) to their portfolio in Q4 2025, for an estimated $2,650,633
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ACRS Analyst Ratings
Wall Street analysts have issued reports on $ACRS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/28/2026
To track analyst ratings and price targets for $ACRS, check out Quiver Quantitative's $ACRS forecast page.
Full Release
WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), will be available during the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. The poster will include results not previously reported from Aclaris’ Phase 2a trial in patients with moderate-to-severe atopic dermatitis (AD).
Electronic Poster Details:
| Title | Results from an Open-Label Phase 2 Trial of ATI-2138, an Investigational Oral Covalent Inhibitor of Interleukin-2-Inducible T Cell Kinase (ITK) And Janus Kinase 3 (JAK3), in Patients with Moderate-To-Severe Atopic Dermatitis |
| Authors | Ajay Aggarwal 1 , Aparna Kaul 1 , Loreen Stillwell 1 , Nancy McGraw 1 , Robert Mahe 1 , Rakesh Basavalingappa 1 , Emma Huff 1 , David R. Anderson 1 , Emma Guttman 2 , Joseph Monahan 1 , Neal Walker 1 |
| Affiliations: 1 Aclaris Therapeutics Inc.; 2 Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY | |
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on
LinkedIn
.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]
